t-dm1
they have closed the phase 2 third line study.. which was much more open..
genentech is on the homestretch to approval.. so now they are tightening the requirements to get into further studies..
they have the pivotal phase 3 head to head with tykerb / xeloda vs tdm1 280 pts in each arm.. should be enrolled within 9-12 months
also have first line trial in phase 2 100 pts vs taxotere for newly diagnosed MBC pts..
soon to begin will be a phase 1 trial with tdm1 + pertuz..this will start by june.. supposed to be farely nonrestrictive.
|